ŞENGÜL SAMANCI, N. Et Al. 2020. Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma. MELANOMA RESEARCH , vol.30, no.5 , 477-483.

ŞENGÜL SAMANCI, N., ÇELİK, E., Bagcilar, O., Erol, B. C., Bicki, E., ORUÇ, K., ... Bedir, S.(2020). Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma. MELANOMA RESEARCH , vol.30, no.5, 477-483.

ŞENGÜL SAMANCI, Nilay Et Al. "Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma," MELANOMA RESEARCH , vol.30, no.5, 477-483, 2020

ŞENGÜL SAMANCI, Nilay Ş. Et Al. "Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma." MELANOMA RESEARCH , vol.30, no.5, pp.477-483, 2020

ŞENGÜL SAMANCI, N. Et Al. (2020) . "Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma." MELANOMA RESEARCH , vol.30, no.5, pp.477-483.

@article{article, author={Nilay ŞENGÜL SAMANCI Et Al. }, title={Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma}, journal={MELANOMA RESEARCH}, year=2020, pages={477-483} }